Salivary oncofoetal fibronectin and oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 29, Issue 6, 2000, Pages 267-270

  Lyons, A J ^a,c   Cui, N ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b School of Stomatology   (China)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Oncofoetal fibronectin; Oral carcinoma; Saliva

Indexed keywords

ALTERNATIVE RNA SPLICING; CARCINOMA CELL; DISEASE DETECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRONECTIN; GLYCOPROTEIN; SALIVA; SQUAMOUS CELL CARCINOMA; TUMOR DIAGNOSIS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FIBRONECTINS; GLYCOSYLATION; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROTEIN ISOFORMS; SALIVA; TUMOR MARKERS, BIOLOGICAL;

EID: 0034085489     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0714.2000.290605.x     Document Type: Article

References (12)

1. Hynes RO. Fibronectins. Sci Am 1986; 254: 32-41.
2. Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin; structure, physiological occurrence and histopathological aspects. Virchows Arch 1996; 429: 311-22.
3. Matsura H. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumour tissues and its absence from normal adult tissues and plasma. Proc Nat Acad Sci USA 1985; 82: 6517-21.
4. Mandel U, Gaggero B, Reibel J, Hamilton Therkildsen M, Dabelsteen E, Clausen H. Oncofetal fibronectins in oral carcinomas: correlation of two different types. APMIS 1994; 102: 695-702.
5. Lockwood CJ, Senyai AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325: 629-34.
6. Feinberg RF, Kliman HJ, Bedian V, Monzon-Bordonaba F, Menzin AW, Wang CL. Monoclonal antibody X184A identifies an oncofetal fibronectin epitope distinct from the FD-6 binding site. Am J Obstet Gynecol 1995; 172: 126-42.
7. Ylatupa S, Haglund C, Mertaniemi P, Vahtera E, Partanen P. Cellular fibronectin in serum and plasma: a potential new tumour marker? Br J Cancer 1995; 71: 578-81.
8. Katayama M, Hino F, Kamihagi K, Sekiguchi K, Titani K, Kato I. Urinary fibronectin fragments: a potential tumour marker measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem 1991; 37: 466-71.
9. Webb KS, Lin GH. Urinary fibronectin potential as a biomarker in prostatic cancer. Urol Invest 1980; 17: 401-4.
10. Ogden GR, Chisholm DM, Lane EB. The utility of cytokeratin profiles for detecting oral cancer using exfoliative cytology. Br J Oral Maxillofac Surg 1996; 34: 461-6.
11. Anehisha J, Doi S, Yamanaka T, Takeuchi H. Salivary fibronectin in man: an immunoblotting radioimmunoassay and immunohistochemical study. Arch Oral Biol 1991; 36: 265-72.
12. American Joint Committee on Cancer. Manual for staging of cancer, 3rd edn. Philadelphia: Lippincott, 1989.